All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.
AZD-2207 is a cannabinoid receptor CB1 antagonist and highly lipophilic compound that can be used in studies related to type 2 diabetic disease and obesity.
| Molecular Weight | 605.46 |
| Formula | C25H25Cl2F3N4O4S |
| CAS Number | 866598-45-0 |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Cannabinoid Products |
|---|
| UCM707
UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of Anandamide. |
| SCH 336
SCH 336 is a potent, selective, inverse and orally active CB2 agonist. |
| JTE-907
JTE-907 is a highly selective, orally active CB2 receptor inverse agonist and exerts anti-inflammatory effects in vivo. |
| LEI-101
LEI-101 is a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist, with a pEC50 of 8 for hCB2, and a pKi of less than 4 for hERG. |
| AEF0117
AEF0117 is a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1-SSi). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
